EVALUATION OF SERUM IRISIN WITH LIPID PROFILE IN TYPE-2 DIABETIC PATIENTS IN SULAIMANI
Fenk Bakir Maarouf a, Mohammed O. Mohammed b, Nazaneen Akbar Omer a, and Beston Faiek Nore a, c
a Department of Biochemistry, College of Medicine, University of Sulaimani.
b Department of Medicine, College of Medicine, University of Sulaimani.
c Department of Health, Kurdistan Institution for Strategic Studies and Scientific Research, Sulaimani.
Submitted: 26/5/2018; Accepted: 12/8/2018; Published 15/10/2018
DOI Link: https://doi.org/10.17656/jsmc.10160
Obesity has become one of the most growing global risk factor for many diseases and metabolic disorders, including Type -2 Diabetes Mellitus (T2DM). Irisin is a recently discovered myokine hormone and has a primary structure of 112 amino acids. It is expressed and secreted by muscles in response to physical activities that control obesity and delay insulin resistance. Several studies show decrease in Irisin levels in a number of metabolic disorders, but the Irisin status is unknown in diabetic patients in our region.
To evaluate the level of serum Irisin with serum lipid profile in T2DM patients.
Patients and Methods
This study was carried out on 256 individuals, 156 T2DM patients (study group) and 100 non-diabetic individuals (control group) in Sulaimani diabetic centre. The serum level of irisin, glucose, urea, creatinine, lipid profile, and glycated hemoglobin were determined using biochemical and immunological methods. Statistical analysis was performed using STATA 14 software.
The mean serum Irisin level was significantly higher (P<0.01) in the control group compared to T2DM (3.34±1.48 vs. 1.82±1.44) respectively. The body mass index (BMI) was significantly higher in T2DM patients (31.06 ±5.3) compared to the control (28.55±3.9). The levels of total cholesterol, triglyceride (TG) and low-density lipoprotein (LDL) were significantly higher in T2DM, while high-density lipoprotein (HDL) was lower in T2DM compared to the control. The Atherogenic Index of plasma (AIP) was significantly higher inT2DM (1.9±0.44) compared to the control (1.2±0.59). There was a significant inverse association (p<0.001) between AIP and serum Irisin in both groups.
Serum Irisin was significantly lower in T2DM compared to non-diabetic control. There was a significant inverse correlation between serum Irisin and AIP in both groups. However, there was no significant correlation between serum Irisin with age, gender and BMI in both groups.
Irisin, T2DM, BMI, Obesity, Atherogenic Index, Lipid profile.
1. Piero MN. Diabetes mellitus – a devastating metabolic disorder. Asian J Biomed Pharm Sci. 2015;4(40):1–7.
2. Mooradian A. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab [Internet]. 2009;5(3):150–9. Available from: http://www.nature.com/nrendo/journal/v5/n3/full/ncpendmet1066.html
3. Ferrer-Martínez A, Ruiz-Lozano P, Chien KR. Mouse PeP: A novel peroxisomal protein linked to myoblast differentiation and development. Dev Dyn. 2002;224(2):154–67.
4. Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481(7382):463–8.
5. Hwang Y-C, Jeon WS, Park C-Y, Youn B-S. The ratio of skeletal muscle mass to visceral fat area is a main determinant linking circulating irisin to metabolic phenotype. Cardiovasc Diabetol [Internet]. BioMed Central; 2016;15(1):9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26790404%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4719696
6. Chen J, Huang Y, Gusdon AM, Qu S. Irisin: a new molecular marker and target in metabolic disorder. Lipids Health Dis. 2015;14:2.
7. Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, Schneider BE, et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism. 2012;61(12):1725–38.
8. Choi YK, Kim MK, Bae KH, Seo HA, Jeong JY, Lee WK, et al. Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract. 2013;100(1):96–101.
9. Liu J-J, Wong MDS, Toy WC, Tan CSH, Liu S, Ng XW, et al. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications [Internet]. 2013;27(4):365–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23619195
10. Kanthe PS, Patil BS, Bagali S, Deshpande A, Shaikh GB, Aithala M. Atherogenic index as a predictor of cardiovascular risk among women with different grades of obesity. Int J Collab Res Intern Med Public Heal. 2012;4(10):1767–74.
11. Dobiásová M, Frohlich J, Sedová M, Cheung MC, Brown BG. Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. J Lipid Res. 2011;52(3):566–71.
12. Saleh BO, Majeed MJ, Oreaby GM. Irisin impact as a medication that ameliorate and hinder the development of insulin resistance associated disorders without regular exercise ( experimental study ). 2014;13(9):28–35.
13. CDC. Crude and Age-Adjusted Incidence of Diagnosed Diabetes per 1,000 Population Aged 18–79 Years, United States, 1980–2011. Diabetes Public Health Resource. 2014.
14. Scott RA, Langenberg C, Sharp SJ, Franks PW, Rolandsson O, Drogan D. Europe PMC Funders Group The link between Family History and risk of Type 2 Diabetes is Not Explained by Anthropometric , Lifestyle or Genetic Risk Factors : the EPIC-InterAct Study. 2014;56(1):60–9.
15. Ahmad NS, Islahudin F, Paraidathathu T. Factors associated with good glycemic control among patients with type 2 diabetes mellitus. J Diabetes Investig. 2014;5(5):563–9.
16. Hachem SB, Mooradian AD. Familial dyslipidaemias: An overview of genetics, pathophysiology and management. Vol. 66, Drugs. 2006. p. 1949–69.
17. Taskinen MR. Diabetic dyslipidaemia: From basic research to clinical practice. Vol. 46, Diabetologia. 2003. p. 733–49.
18. Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in type 2 diabetes: Prevalence, pathophysiology, and management. Drugs. 2013;73(4):327–39.
19. Rajab T. Study for Atherogenic Index of Plasma (Aip) in Patients With Type1 Diabetes Mellitus, Type2 Diabetes Mellitus, Betathalassemia. Ijcsr [Internet]. 2012;02i2:1–9. Available from: http://www.doaj.org/doaj?func=fulltext&aId=1082638
20. Tan MH, Johns D, Glazer NB. Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. Clin Chem. 2004;50(7):1184–8.
21. Niroumand S, Khajedaluee M, Khadem-Rezaiyan M, Abrishami M, Juya M, Khodaee G, et al. Atherogenic Index of Plasma (AIP): A marker of cardiovascular disease. Med J Islam Repub Iran. 2015;29(1):627–35.
22. Moreno-Navarrete JM, Ortega F, Serrano M, Guerra E, Pardo G, Tinahones F, et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab. 2013;98(4):E769-78.
23. Wu J, Bostr??m P, Sparks LM, Ye L, Choi JH, Giang AH, et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell. 2012;150(2):366–76.
24. Majeed MJ, Saleh O. Descriptive Consideration of Serum Irisin Levels Various Factors: Obesity, Type 2 Diabetes Mellitus, Pre-Diabetic Status, Gender, and Athletics. J Diabetes Metab [Internet]. 2014;5(12). Available from: http://www.omicsonline.org/diabetes-metabolism-abstract.php?abstract_id=36605
25. Jameel F, Thota RN, Wood LG, Plunkett B, Garg ML. Sex-dependent association between circulating irisin levels and insulin resistance in healthy adults. J Nutr Intermed Metab [Internet]. Elsevier Inc; 2015;2(3–4):86–92. Available from: http://linkinghub.elsevier.com/retrieve/pii/S2352385915300086
26. Zhang HJ, Zhang XF, Ma ZM, Pan LL, Chen Z, Han HW, et al. Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. J Hepatol. 2013;59(3):557–62.
© The Authors, published by University of Sulaimani, College of Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.